LncRNA SNHG10 is downregulated in non-small cell lung cancer and predicts poor survival
- PDF / 1,057,532 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 4 Downloads / 173 Views
RESEARCH ARTICLE
Open Access
LncRNA SNHG10 is downregulated in nonsmall cell lung cancer and predicts poor survival Meng Liang1†, Linlin Wang2†, Chuanhua Cao3, Shimao Song1 and Feng Wu1*
Abstract Background: LncRNA SNHG10 has been reported to be an oncogenic lncRNA in liver cancer. However, its roles in non-small cell lung cancer (NSCLC) remains unknown. Methods: Tumor and paired non-tumor tissues were harvested from 62 NSCLC patients. RT-qPCR was used to detect the expression of SNHG10 and miR-21 in tissues. Overexpression experiments were used to evaluate the interaction between SNHG10 and miR-21 in NSCLC cells. CCK-8 assay was used to detect the cell proliferation. Results: We observed the expression of SNHG10 was down-regulated in non-small cell lung cancer (NSCLC) compared with that in non-tumor tissues. Moreover, we found that high expression levels of SNHG10 predicted favorable survival of NSCLC patients, and the expression of miR-21 were increased in NSCLC and inversely correlated with SNHG10 expression. In NSCLC cells, overexpression of SNHG10 resulted in increased miR-21 gene methylation and decreased miR-21 expression. Moreover, overexpression of SNHG10 attenuated the enhancing effect of miR-21 overexpression on cell proliferation. Conclusions: SNHG10 may involve in NSCLC cell proliferation by regulating the miR-21 gene methylation. Keywords: SNHG10, miR-21, NSCLC, Methylation
Background Non-small cell lung cancer (NSCLC) is the major subtype of lung cancer and is the main cause of cancerrelated deaths worldwide [1]. NSCLC has two major subtypes including lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) [2]. Despite of the advances have been made on the treatment and diagnosis of NSCLC, only less than 15% of NSCLC patients can survive for more than 5 years [3]. Therefore, more effective therapeutic approaches are needed. Smoking is the major risk factor for NSCLC [4]. * Correspondence: [email protected] † Meng Liang and Linlin Wang contributed equally to this work. 1 Department of Oncology Taihe Hospital, Hubei University of Medicine, 32 South Renmin Road, Shiyan, Hubei 442000, People’s Republic of China Full list of author information is available at the end of the article
However, never-smokers also develop NSCLC [5], suggesting the involvement of other factors, such as genetic factors, in the molecular pathogenesis of NSCLC [6]. It has been well established that molecular players participate in nearly all aspects of the occurrence and development of NSCLC [7, 8]. Increased understanding of the molecular mechanism of NSCLC provides novel targets for the development of anti-cancer approaches, such as targeted therapy [9, 10]. LncRNAs are emerging critical players in cancer biology and they participate in cancer mainly by regulating the expression of cancer-related genes [11, 12]. Therefore, lncRNAs are potential targets for cancer targeted therapy [13]. SNHG10 has been characterized as an oncogenic lncRNA in liver cancer [14]. However, we observed the downregulation of SNHG10 in NSCL
Data Loading...
